Gaush Meditech (HKSE:02407) ROCE % : 7.80% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Gaush Meditech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gaush Meditech's annualized ROCE % for the quarter that ended in Jun. 2024 was 7.80%.

Gaush Meditech ROCE % Historical Data

The historical data trend for Gaush Meditech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gaush Meditech ROCE % Chart

Gaush Meditech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

0.87

19.78

-3.74

-10.56

14.13

Gaush Meditech Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial				-1.13	-20.55	15.64	13.51	7.80

Gaush Meditech ROCE % Calculation

Gaush Meditech's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	326.319	/	( ( (3035.331 - 550.119)	+	(3110.398 - 975.287) )	/ 2 )
	=	326.319	/	( (2485.212	+	2135.111)	/ 2 )
	=	326.319	/	2310.1615
	=	14.13 %

Gaush Meditech's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	170.09	/	( ( (3110.398 - 975.287)	+	(3022.688 - 796.724) )	/ 2 )
	=	170.09	/	( ( 2135.111	+	2225.964 )	/ 2 )
	=	170.09	/	2180.5375
	=	7.80 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Gaush Meditech (HKSE:02407) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Gaush Meditech ROCE % Related Terms

Thank you for viewing the detailed overview of Gaush Meditech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gaush Meditech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gaush Meditech Ltd (HKSE:02407) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.11 Dongzhimen South Avenue, Room 1901, Building A, Zhonghui Plaza, Dongcheng District, Beijing, CHN

Website

https://www.gaush.com

Gaush Meditech Ltd is a provider of a broad spectrum of ophthalmic medical devices. The segments of the company include 1) Proprietary products segment develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; 2) Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; 3) Technical services segment provides warranty services, maintenance services and after-sales services related consumables; and 4) Others segment.

Executives

Orbimed Advisors Iii Limited	2102 Investment manager
Orbimed Asia Gp Iii, L.p.	2102 Investment manager
Orbimed Asia Partners Iii, L.p.	2102 Investment manager
Gao Tieta	2201 Interest of corporation controlled by you
Gaush Holding Ltd	2101 Beneficial owner
Cuprite Gem Investments Ltd	2101 Beneficial owner
Warburg Pincus (bermuda) Private Equity Gp Ltd.	2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp Llc	2201 Interest of corporation controlled by you
Warburg Pincus (cayman) China-southeast Asia Ii Gp, L.p.	2201 Interest of corporation controlled by you
Warburg Pincus China-southeast Asia Ii (cayman), L.p.	2201 Interest of corporation controlled by you
Warburg Pincus Partners Ii (cayman), L.p.	2201 Interest of corporation controlled by you

Gaush Meditech Headlines

No Headlines